Business
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease Lausanne, Switzerland, March 20, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer’s disease. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, commented: “The ten presentations during this AD/PDTM conference demonstrate AC Immune’s progress towards our over-arching goal, which is to shift the treatment paradigm towards Precision Medicine and disease prevention. As our clinical programs in Alzheimer’s and Parkinson’s diseases are advancing, we are solidifying our position as a leading developer of vaccines for neurodegenerative diseases. AC Immune’s cutting-edge therapeutic and diagnostic research programs pursuing multiple validated molecular targets, highlight the breadth of our pipeline. These will drive our differentiated Precision Medicine approach in neurodegeneration and become substantial value creating catalysts.” AC Immune presentations at AD/PDTM2023 (all times are CEST) Roundtable discussionForum 02: Immunotherapies in AD: from basics to approvalDate: Wed, 29.03.2023 | 03:55 PM - 04:55 PM | Hall CPanelist: Forum discussion with Johannes Streffer, M.D., (AC Immune) Active immunotherapyABATE study – Utilizing biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimer’s diseaseDate: Sat, 01.04.2023 | 05:55 PM - 06:10 PM | Hall G3Presenter: Oral presentation by Johannes Streffer, M.D., (AC Immune) Beneficial effect of ACI-24 vaccination on Abeta plaque pathology and microglial phenotypes in an amyloidosis mouse modelDate: Sat, 01.04.2023 | 09:25 AM - 09:40 AM | Hall G4Presenter: Oral pres...